openPR Logo
Press release

Orphan Drugs Market to Witness Robust Expansion Throughout the Forecast Period 2017 - 2025

09-28-2017 08:44 AM CET | Health & Medicine

Press release from: TMR - Research Reports

Orphan Drugs Market to Witness Robust Expansion Throughout

The global orphan drugs market is projected to display a healthy 12.1% CAGR from 2017 to 2025, for the market to reach a valuation of US$318.5 bn by the end of 2025.

Oncology to Remain Dominant Disease Type Segment through 2025

Vis-à-vis revenue, in 2016, oncology stood as the dominant segment based on disease type, and is expected to hold on to its dominant position over the forecast period. The increasing genetic mutations and the increasing burden of rare cancers are attributed to the growth of this segment.

View and Download TOC of Orphan Drugs Market Research Report@ https://www.transparencymarketresearch.com/report-toc/1254

In terms of product type, biologic products led the market in 2016 on the basis of revenue. The segment is expected to display a significant CAGR over the forecast period backed by factors such as high efficacy, fewer side effects, and difficulty to develop generic versions of these drugs. Hospital pharmacies led the global orphan drugs market in terms of revenue in 2016 amongst all distribution channel segments.

North America held the leading share of the orphan drugs market in 2016. Within North America, the U.S. is a leading domestic market contributing substantial revenue to this market.

Government Aid and Tax Credits for Development of Orphan Drugs Benefits Market

As per an analyst at TMR, the global orphan drugs market is anticipated to expand at a significant growth rate on account of a number of factors. Amongst all, high return on investments for the development of orphan drugs is a key one. The development of phase- III orphan drugs costs over 50% more than the cost of development of non-orphan drugs. The return on investments is estimated to be over 1.2 times greater for phase- III orphan drugs than non-orphan drugs.

Request and Download Sample Report@ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1254

In developed countries, strong focus on research and development of orphan drugs, which receives government aid, tax credits, and fee waivers is contributing to the growth of this market. As per records of the Research Office Legislative Council Secretariat, there are more than 30 million individuals suffering from rare diseases in the U.S. As a result, 4,171 drugs have received orphan drug status in the U.S., which is attracting drug manufacturers to invest in this market.

Furthermore, increasing number of rare diseases that are related to genetic reasons leading to investments for drug development of these diseases is benefitting the orphan drugs market. As per statistics of Global Genes, a non-profit organization, more than 7,000 types of rare diseases have been identified globally. At present, more than 300 million people worldwide are estimated to be affected by rare diseases that calls for considerable production of orphan drugs.

In a moderately consolidated global orphan drugs market, players are primarily focused on strategic acquisitions and are strategizing to gain maximum returns on investments made for R&D of orphan drugs and to leverage the incentives offered by governments for research on orphan drugs, according to recent market intelligence by Transparency Market Research. In this scenario, some of the companies to hold a commanding position in the global orphan drugs market are Novartis AG, Celgene Corporation, Pfizer Inc., Alexion Pharmaceuticals Inc., GlaxoSmithKline plc, and Johnson & Johnson.

Buy Full Orphan Drugs Market Report@ https://www.transparencymarketresearch.com/checkout.php?rep_id=1254<ype=S

About TMR

Transparency Market Research (TMR) is a global market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of Analysts, Researchers, and Consultants, use proprietary data sources and various tools and techniques to gather and analyze information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

US Office Contact

90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com/

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Orphan Drugs Market to Witness Robust Expansion Throughout the Forecast Period 2017 - 2025 here

News-ID: 744896 • Views: 269

More Releases from TMR - Research Reports

Pulmonary Drugs Market is Expected to Reach US$ 28,082.1 Million by the End of 2 …
According to the research report, the global pulmonary drugs market is expected to be worth US$ 28,082.1 mn by the end of 2024 as compared to US$ 48,039.7 mn in 2015. Analysts calculate that the global market will plummet at a CAGR of -6.3% during the forecast period of 2016 and 2024. The market will thrive as the demand for combination drugs is anticipated to remain on the rise during
North America Ventricular Assist Device Market is rising to a valuation of US$ 1 …
According to TMR, the opportunity in the North America market for VADs, which stood at US$0.4 bn in 2015, is likely to expand at a healthy CAGR of 9.20% between 2016 and 2024 and increase to US$1.07 bn by the end of the forecast period. The destination therapy (DT) segment has been reporting a greater application of VADs than the other two indication segments. It is expected to remain the
Dental Membrane and Bone Graft Substitutes Market to rise to US$ 922.6 Million b …
Transparency Market Research notes that innovation and expansion into emerging regions have served these companies well in strengthening their hold in the dental membrane and bone graft substitutes market. For instance, Switzerland-based Geistlich Pharma AG - a global manufacturer and supplier of dental products and devices - expanded its operations in Sydney, Australia and New Delhi, India in 2016. The global dental membrane and bone graft substitutes market is expected to
Human Vaccines Market is Estimated to Reach US$ 72.5 Billion by 2024
The global human vaccines market was valued at US$28.3 bn in 2015 and is estimated to reach US$72.5 bn by 2024, registering an 11.2% CAGR during the forecast period. By age group, pediatric vaccines accounted for a 57.5% share in the global human vaccines market in 2015. Adult vaccines, on the other hand, are expected to expand at a 13.2% CAGR from 2016 to 2024. Based on product, the pneumococcal segment

All 5 Releases


More Releases for Orphan

Protalex receives orphan drug designation for ITP
Protalex, a biopharmaceutical company dedicated to develop orphan drug or therapies for the effective treatment of patients with rare diseases, has recently announced that its novel drug candidate, PRTX 100 has been granted orphan drug designation by the US Food and Drug Administration (FDA) for the treatment of persistent, chronic immune thrombocytopenia (ITP). PRTX-100 is currently being evaluated in its Phase ½ trial in patients who have previously been treated with
US Orphan Drug Pipeline Analysis
In recent years, the pharmaceutical industry has been experiencing a paradigm shift. While a large pool of patients was considered as a major source of revenue for pharma companies in the past, the focus is now gradually shifting to small sections of patients suffering from rare disease. In US, this pool of patients is gradually growing and orphan drugs are becoming an extremely attractive business proposition for the pharmaceuticals industry.
Europe Orphan Drugs Pipeline Analysis
“Europe Orphan Drugs Pipeline Analysis” by PNS Pharma gives comprehensive insight on the various drug profiles under Orphan Drugs status in Europe. Research report covers all the ongoing drug development in various phases. Each drug profiles include detailed information like: Originator, Owner, Collaborator, Technology Provider, Licensee, Development Phase, Development Indications, Mechanism of Action, Chemical Formula, Country of Development and detailed analysis on the development process. The information for particular drug
Global Orphan Drug Pipeline Analysis
In recent years, the pharmaceutical industry has been experiencing a paradigm shift. While a large pool of patients was considered as a major source of revenue for pharma companies in the past, the focus is now gradually shifting to small sections of patients suffering from rare disease. In US & Europe, this pool of patients is gradually growing and orphan drugs are becoming an extremely attractive business proposition for the
Europe Orphan Drug Pipeline Analysis 2014
Rare diseases are classified as those that affect fewer than 200,000 in the United States and less than 5 in 10,000 in the EU. The term “orphan” was associated with these drugs in order to reflect the lack of interest by pharma companies. In the European Union, orphan drugs are known as orphan medicinal products. Many treatments which are commercially available in today’s world lack the ability to address most
Global Orphan Drug Clinical Pipeline Insight 2022
“Global Orphan Drug Clinical Pipeline Insight 2022” report gives comprehensive insight on various clinical and non-clinical aspects associated with ongoing clinical trials of 808 orphan designated drugs across the globe. The in-depth clinical insight presented in the report helps the reader to analyze and identify the various stakeholders involved in the clinical development and commercialization of orphan designated drugs in the global market. Currently there are more than 300 orphan